Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lymphoma

Lymphoma

Part of Cancer

Subtypes of Lymphoma

Non-Hodgkin's Lymphoma 7 Hodgkin lymphoma 2

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lymphoma

314 trials tracked for Lymphoma: 34 in phase 3 or 4 and 12 with published results. The most-cited published study has 1325 citations.

314Trials tracked
34Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 3 Phase 3 31 Phase 2 219 Phase 1 33 Other / NA 28
  1. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed · 1,325 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 618 cited
  3. Phase 3 TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Completed · 558 cited
  4. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  5. Phase 3 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed · 255 cited
  6. Phase 3 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed · 155 cited
Show 44 more trials
  1. Phase 3 Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS Completed · 109 cited
  2. Phase 3 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Completed · 50 cited
  3. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 27 cited
  4. Phase 3 Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma Completed · 26 cited
  5. Phase 4 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection Completed · 16 cited
  6. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 16 cited
  7. Phase 4 Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Completed
  8. Phase 4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed
  9. Phase 3 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed
  10. Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed
  11. Phase 3 A Study of Actonel for the Prevention of Bone Loss Completed
  12. Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Completed
  13. Phase 3 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed
  14. Phase 3 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed
  15. Phase 3 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed
  16. Phase 3 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss Completed
  17. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed
  18. Phase 3 A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma Completed
  19. Phase 3 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed
  20. Phase 3 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed
  21. Phase 3 Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed
  22. Phase 3 Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) Completed
  23. Phase 3 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Completed
  24. Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed
  25. Phase 3 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed
  26. Phase 3 S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma Completed
  27. Phase 3 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed
  28. Phase 3 Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed
  29. Phase 2 A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies Completed
  30. Phase 2 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation Completed
  31. Phase 2 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients Completed
  32. Phase 2 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed
  33. Phase 2 Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Completed
  34. Phase 2 A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed
  35. Phase 2 Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma Completed
  36. Phase 2 Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma Completed
  37. Phase 2 PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients Completed
  38. Phase 2 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders Completed
  39. Phase 2 Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY Completed
  40. Phase 2 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Completed
  41. Phase 2 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed
  42. Phase 2 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed
  43. Phase 2 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed
  44. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed

Showing the 50 most-cited and recently-updated of 314 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Lymphoma: what the trials found

Newer evidence indicates that Lenalidomide significantly improves progression-free survival (PFS) and objective response rates (ORR) compared to standard treatments 10. Additionally, the use of Tacrolimus has been shown to improve graft-versus-host disease (GVHD) and relapse or progression-free survival (GRFS) at one year while reducing the incidence of chronic GVHD 12.

In terms of supportive care and management, Apixaban was associated with a lower number of non-fatal DVT, PE, CVST, and VTE-related deaths compared to alternative treatments 17. NiCord (omidubicel) demonstrated improved outcomes regarding the timing of bacterial/fungal infections, days alive out of hospital, and platelet engraftment post-transplantation 16.

Several interventions have been evaluated for specific complications or supportive measures. Ethanol lock therapy was studied in a Phase 4 trial 7, while filgrastim showed consistent outcomes across multiple study arms regarding 3-year event-free survival, progression-free survival, and overall survival 20. Risedronate (Actonel) was evaluated for its role in bone loss reduction over 6 to 12 months 22.

Other established treatments include rituximab [1, 13], bendamustine 18, and autologous hematopoietic stem cell transplantation 19. Regarding side effect management, a combination of baclofen, amitriptyline, and ketamine gel showed no significant difference in sensory or motor neuropathy scores 14, and cyclosporine ophthalmic emulsion did not significantly impact the development of ocular GVHD 15.

Recent results — preliminary, needs further review

  • • FF-10502-01 was evaluated for progression-free survival (PFS) and stable disease duration, though specific median values varied across study arms 2.
  • • LY3039478 showed an objective response rate (ORR) of 0% across all trial parts 4.
  • • Rituximab Pfizer was evaluated in a large-scale phase study 5.
  • • Transfusion support was assessed regarding ICU duration and chemotherapy administration timing in the final days of life 6.

For the clinician treating this condition

  • Lenalidomide provides statistically significant improvements in both progression-free survival and objective response rates 10.
  • Tacrolimus is effective in improving one-year GRFS and reducing chronic GVHD incidence post-transplant 12.
  • Apixaban significantly reduces the risk of non-fatal DVT, PE, and CVST compared to alternative treatments 17.

AI synthesis of 15 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
Anesthesiology & Pain Medicine Sys. Review
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma New Strategies to Keep CAR-T Cells Strong Against Cancer
This narrative review examines strategies to prevent CAR-T cell exhaustion in patients with treatment-resistant non-Hodgkin lymphoma.
This review explains how to stop immune cells from giving up on fighting cancer.
Frontiers Apr 22, 2026
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Drug Pipeline Sys. Review
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Frontiers Apr 18, 2026
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Oncology Cohort
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
medRxiv Apr 14, 2026
Systematic review finds highest glyphosate exposure associated with increased NHL risk
Oncology Sys. Review
Systematic review finds highest glyphosate exposure associated with increased NHL risk Higher glyphosate herbicide exposure linked to increased lymphoma risk in research review
A systematic review and meta-analysis of 20 observational study populations found that ever exposure to glyphosate-based herbicides was not …
People with the highest glyphosate herbicide exposure had about a 38% higher chance of developing non-Hodgkin's lymphoma compared to those w…
medRxiv Apr 4, 2026

Research across Cancer

Related studies from across the Cancer family.

Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Oncology Meta-analysis
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Jul 12, 2026
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
Allergy & Immunology Sys. Review
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Frontiers Jun 11, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Allergy & Immunology Sys. Review
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Frontiers May 15, 2026
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy
Oncology Sys. Review
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy When a Skin Rash Signals a Hidden Blood Cancer
This case report and literature review examines cutaneous manifestations in a 63-year-old male with Angioimmunoblastic T-cell lymphoma treat…
A rare lymphoma can hide behind common-looking skin rashes and ulcers, causing dangerous delays in diagnosis that may last months.
Frontiers May 14, 2026
Literature review on primary CNS MALT lymphoma treatment and diagnosis
Oncology Sys. Review
Literature review on primary CNS MALT lymphoma treatment and diagnosis A Rare Brain Tumor in the Ventricles Was Found and Treated
This literature review and case report describes a 62-year-old man with primary central nervous system mucosa-associated lymphoid tissue lym…
A 62-year-old man had a rare brain tumor inside a fluid-filled ventricle, and a new treatment plan kept it from coming back.
Frontiers May 11, 2026
Narrative review of treatment strategies for primary central nervous system lymphoma
Dermatology Sys. Review
Narrative review of treatment strategies for primary central nervous system lymphoma A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
Frontiers May 8, 2026
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
Oncology Meta-analysis
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
May 3, 2026
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients
Hematology Meta-analysis
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients Early PET scans help doctors predict how well large B-cell lymphoma treatments will work for patients
This systematic review and meta-analysis evaluated the utility of interim FDG PET (iPET) in 44 eligible studies involving large B-cell lymph…
A review of many studies shows that early PET scans can tell doctors if cancer treatment is working. This helps them decide the best next st…
May 2, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
Oncology Sys. Review
Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART 1. HEADLINE
This case report and literature review describes a 66-year-old male with stage IV HIV-associated diffuse large B-cell lymphoma.
HIV Treatment Clears Advanced Lymphoma Without Chemo
Frontiers Apr 29, 2026

Questions about Lymphoma

Which EBUS technique works best for diagnosing lymphoma in the mediastinum?

EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) has the highest diagnostic yield for lymphoma in the mediastinum, outperforming standard EBUS-TBNA.

Full answer →